(2R,3R,11BR)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl l-valinate,
NBI-98854,
valbenazine,
valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester,
Valbenazine,
1025504-45-3,
Ingrezza,
UNII-54K37P50KH,
NBI 98854,
54K37P50KH,
L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester;L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester,
Valbenazine [USAN:INN],
L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester,
L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester,
Valbenazine (USAN/INN),
GTPL8694,
CHEMBL2364639,
SCHEMBL15932979,
GEJDGVNQKABXKG-CFKGEZKQSA-N,
EX-A2002,
MFCD28963976,
ZINC43195697,
CS-5908,
DB11915,
SB17456,
Valbenazine pound NBI-98854 pound(c),
AS-35294,
HY-16771,
D10675,
NBI-98854;NBI98854;NBI 98854,
(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate,
(2R,3R,11bR)-9,10-Dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl L-valinate,
(S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester,
[(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl] (2S)-2-amino-3-methylbutanoate,
Valbenazine tosylate,
Valbenazine [USAN],
Valbenazine ditosylate,
NBI-98854,
D0IX1I,
NBI-98782,
VMAT-2 inhibitor (CNS disease), Neurocrine,
Vesicular monoamine transporter 2 inhibitor (CNS indications), Neurocrine,